Hypericin-PVP Complex via Glass Transition Heating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hypericin-PVP complexes are not suitable for applications requiring large quantities of hypericin due to their low hypericin content, leading to excessive use of polyvinylpyrrolidone (PVP) and associated side effects, which is a limitation in photodynamic therapy and other therapeutic methods.
Innovation Solution
A hypericin-PVP complex with a higher proportion of hypericin by weight, exceeding 6%, is achieved by heating a mixture of hypericin and PVP above the glass transition temperature of PVP, allowing for the production of complexes with hypericin content up to 35% or more, thereby reducing the amount of PVP required.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional hypericin-PVP complexes with low hypericin content are used, then water solubility is achieved, but the hypericin concentration is too low for effective therapy requiring large quantities of hypericin
Solution Approach 1:
The patent changes the key parameter of hypericin-PVP complex composition by heating the mixture above the glass transition temperature of PVP (100-200°C), which fundamentally alters the complex formation process and results in a product with dramatically higherhypericin content (>6% by weight, up to 35% or more) compared to conventional complexes. This parameter change resolves the contradiction by enabling effective therapeutic hypericin concentrations while minimizing the amount of PVP required.
Solution Approach 2:
The patent exploits the glass transition phase transition of PVP as a critical control point in the complex formation process. By heating above the glass transition temperature (Tg) of PVP, the system transitions from a glassy state to a more mobile state, enabling enhanced complex formation betweenhypericin and PVP. This phase transition mechanism allows for superior complex formation with higherhypericin content, resolving the contradiction between achieving water solubility and maintaining effective hypericin concentration.
2Reliability
If hypericin is used in high concentrations for effective therapy, then therapeutic effectiveness improves, but PVP side effects increase due to excessive PVP usage
Solution Approach 1:
By changing the composition parameter through heating above PVP's glass transition temperature, the patent achieves a fundamental improvement inhypericin content (>6% by weight, up to 35% or more). This parameter change directly resolves the contradiction by enabling the use of smaller total amounts of complex to achieve the same therapeutic hypericin dose, thereby reducing PVP-related side effects while maintaining or improving therapeutic effectiveness.
3Stability of the object's composition
If conventional complex formation methods are used, then water solubility is achieved, but the hypericin content remains below 6% by weight
Solution Approach 1:
The patent utilizes the glass transition phase transition of PVP as a critical control mechanism. By heating above the Tg of PVP (100-200°C depending on molecular weight), the system transitions to a state that enables superior complex formation. This phase transition approach maintains the water solubility benefit of PVP complexes while dramatically increasinghypericin content to >6% by weight, resolving the contradiction between solubility and concentration.
Solution Approach 2:
The patent implements a fundamental parameter change by controlling the thermal history of the complex formation process. Heating above the glass transition temperature of PVP alters the physical state and molecular mobility, enabling much higherhypericin incorporation into the complex. This parameter change resolves the contradiction by achieving both water solubility (through PVP complexation) and highhypericin content (>6% by weight).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the formulation of water-soluble compositions with higher hypericin concentrations, minimizing PVP usage and associated side effects, facilitating more effective photodynamic therapy and other applications, including antiviral and antibacterial uses, while maintaining the photophysical properties of hypericin.
Implementation Method 1
heating a mixture ofhypericin and PVP above the glass transition temperature of PVP
Data Source
AI summary
The invention relates to a complex that consists of hypericin or a hypericin salt and polyvinyl pyrrolidone (PVP), the average mass fraction of hypericin or hypericin salt in the entire complex being higher than 6% by weight. The invention further relates to a process for preparing said hypericin-PVP complex, according to which process a mixture of hypericin and PVP is heated to a temperature above the glass transition temperature of the PVP used.